Friday, October 23, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 18, 2026

Here are 3 forces that drove a remarkable, record-setting week on Wall Street

View original at cnbc.com
Here are 3 forces that drove a remarkable, record-setting week on Wall Street You can call it a comeback…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The war was very close to over

    60% confidence
  • The Club plans to eventually exit Palo Alto and put some of those funds into CrowdStrike

    60% confidence
  • As AI models get more advanced, it should actually be a tailwind for cybersecurity companies including CrowdStrike and Palo Alto Networks

    60% confidence
  • Consumers are spending more than a year ago, which includes spending more on gas, but they haven't slowed spending on everything else

    60% confidence
  • Microsoft management needs to allocate more of its available compute capacity to Microsoft Azure rather than to Copilot

    60% confidence
  • Goldman Sachs is the one bank you really want to own because that was actually a really good quarter

    60% confidence
  • There could be more gains in stocks that have been pressured by the war if good news keeps coming

    60% confidence
  • There is a coming rotation into stocks that were pressured by the war

    60% confidence
  • Consumers and small businesses remain resilient

    60% confidence
  • The S&P 500 went from near correction territory (down about 9% from its all-time peak) back to an all-time high in just 11 trading days, the fastest move to record levels from a bottom of at least 9% since at least 1990

    60% confidence
  • Before the war-driven surge in energy prices, gas accounted for 6% of total debit card spending and 4% of total credit spending, with each level rising 1%

    60% confidence

Data points we hold from this source

NASDAQ · weekly return6 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,426 source documents archived
Query this data → isubstrate.com